Synairgen share price fluctuations continue! Here’s what I’d do

The Synairgen share price continues its volatile streak but investors are still confident as they snap up newly issued shares for a premium. Is it risky?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Synairgen (LSE:SNG) has yet again surprised the markets, as its share price continues to enjoy a fantastic 2020. The company issued £87m worth of new shares this week, and investors were snapping up them up with glee. By the end of Wednesday, the Synairgen share price had climbed 16% since the start of the week.

Cashing in on Covid-19

Synairgen is a pharmaceutical company specialising in respiratory drug development. Being in a prime position to help combat Covid-19, its share price has risen an astronomical 3,420% year-to-date. From January to April it had risen 1,360%. It then halved, but between July and November it’s risen a further 400%. Given the extreme volatility the share price has seen in this period, it’s clearly not a stock for the faint of heart. It doesn’t offer a dividend, and it’s listed on the notoriously erratic FTSE AIM index. 

The company’s key selling point is its drug SNG001, which has proved effective in treating the more serious side effects of Covid-19. In particular, it markedly reduced breathlessness in patients who received SNG001 compared to those receiving a placebo.

For now, the drug is yet to be licensed, and is still in phase 2 of trials. But that’s not stopped the Synairgen share price rocketing as the company has signed deals with several global partners.

Is it all downhill from here?

Investors are rightly concerned that once the pandemic is under control, Synairgen profits will take a significant hit. But hope springs eternal. Many investors are counting on it making good progress in developing and marketing other drugs in its portfolio.

With its rise to prominence now established on the world stage, there’s no doubt it could continue to grow and prosper. Within the UK it is now a part of a collaborative body of experts in life sciences and progressive research. However, pharmaceuticals is a cut-throat industry, and I think it’s those with a biotech slant that will do the best in the years to come.

Synairgen is one such stock and as such I think it could do very well indeed. Of course, this does depend on how the pandemic evolves and how it progresses its other offerings. I think the Synairgen stock remains a risky buy, particularly at an inflated price point. Nevertheless, it’s down 30% from its summer high, so there could be room for further growth yet.

An acquisition target?

In another scenario, it may get snapped up by a bigger pharma player, particularly if it has the makings of drugs in demand. Severe asthma and COPD continue to plague children and the elderly around the world. The pandemic has highlighted the need for treatments.

Just a quick glance at Synairgen’s share price fluctuations year-to-date tells me this is in no way a safe and sure-fire investment. Still, I do think it’s got a lot going for it and if I owned it, I’d be holding for now.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kirsteen has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »